NASDAQ$HRMY
Harmony Biosciences Holdings Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Harmony Biosciences reported strong Q2 2021 results, driven by WAKIX sales and strategic initiatives.
Harmony Biosciences reported a strong second quarter in 2021, marked by significant revenue growth from WAKIX, strategic progress in clinical development, and a new financing collaboration with Blackstone.
- Net revenue for WAKIX reached $73.8 million, a 24% increase from Q1 2021.
- The average number of patients on WAKIX increased by 15% to approximately 3,200.
- Harmony Biosciences acquired HBS-102, a potential first-in-class molecule for narcolepsy.
- The company entered into a strategic financing collaboration with Blackstone, providing up to $330 million in capital.
Headline financials
Revenue & EPS history
Harmony Biosciences · Revenue · Quarterly
$73.8M
Revenue by segment
Harmony Biosciences · $73.8M total across 1 segment · Q2 2021
- WAKIX Net Product Revenue$73.8M+94.2%100.0%
Forward guidance
Harmony Biosciences anticipates continued quarter-over-quarter revenue growth with normal seasonality, increased investment in R&D and SG&A, and a focus on expanding into additional indications and acquiring new assets.
Tailwinds
- Continued quarter-over-quarter growth in revenue is expected.
- The company is focused on driving continued WAKIX growth.
- Expansion into additional indications that address rare neurological diseases is planned.
- The acquisition of HBS-102 is expected to contribute to future growth.
- The company aims to reinvest capital to fund ongoing development programs and acquire additional assets.
Headwinds
- Normal seasonality during the summer period may impact revenue.
- Increased investment in R&D and SG&A is anticipated.
- The impact of COVID-19 resurgence on business operations is uncertain.
- The exact growth rates moving forward are difficult to speculate.
- There may be increased competition that impacts sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.3%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.0%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+24.4%
Q3 2023
Best reaction
-15.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -8.0% | -1.8% | |
| Q4 2025 | +2.6% | +6.2% | +2.1% | |
| Q3 2025 | -1.6% | -5.1% | +18.1% | |
| Q1 2025 | +7.0% | +13.7% | +16.9% | |
| Q4 2024 | +8.2% | -1.0% | -2.4% | |
| Q3 2024 | -5.5% | -7.5% | +0.0% | |
| Q2 2024 | +8.5% | +9.4% | +15.0% | |
| Q1 2024 | +3.5% | +7.9% | -1.3% | |
| Q4 2023 | -1.5% | +1.5% | +0.9% | |
| Q3 2023 | +24.4% | +31.5% | +47.4% | |
| Q2 2023 | -7.9% | -5.0% | +2.5% | |
| Q1 2023 | +9.9% | +9.5% | +5.0% | |
| Q4 2022 | -6.1% | -8.0% | -15.2% | |
| Q3 2022 | +12.5% | +13.2% | +15.4% | |
| Q2 2022 | +6.3% | +6.6% | -7.8% | |
| Q1 2022 | -15.1% | -21.9% | -5.0% | |
| Q4 2021 | +5.6% | +6.1% | +31.5% | |
| Q3 2021 | +0.1% | -0.1% | -9.3% | |
| Q2 2021 | +13.9% | +20.1% | +41.4% | |
| Q1 2021 | +1.2% | +4.0% | +21.8% | |
| Q1 2020 | +1.2% | +4.0% | +21.8% | |
| Q2 2020 | -4.1% | +11.4% | -2.1% | |
| Q4 2020 | -4.1% | +11.4% | -2.1% | |
| Q3 2020 | -6.8% | -7.4% | -12.0% | |
| Q4 2019 | -6.8% | -7.4% | -12.0% | |
| Q3 2019 | -6.8% | -7.4% | -12.0% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro